Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.
Alsaed B, Lin L, Son J, Li J, Smolander J, Lopez T, Eser PÖ, Ogino A, Ambrogio C, Eum Y, Thai T, Wang H, Sutinen E, Mutanen H, Duàn H, Bobik N, Borenius K, Feng WW, Nabet B, Mustjoki S, Laaksonen S, Eschle BK, Poitras MJ, Barbie D, Ilonen I, Gokhale P, Jänne PA, Haikala HM. Alsaed B, et al. Among authors: gokhale p. Nat Commun. 2025 Jan 2;16(1):28. doi: 10.1038/s41467-024-55378-5. Nat Commun. 2025. PMID: 39747003 Free PMC article.
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Tumors.
Cadzow L, Brenneman J, Tobin E, Sullivan P, Nayak S, Ali JA, Shenker S, Griffith J, McGuire M, Grasberger P, Mishina Y, Murray M, Dodson AE, Gannon H, Krall E, Hixon J, Chipumuro E, Sinkevicius K, Gokhale PC, Ganapathy S, Matulonis UA, Liu JF, Olaharski A, Sangurdekar D, Liu H, Wilt J, Schlabach M, Stegmeier F, Wylie AA. Cadzow L, et al. Among authors: gokhale pc. Cancer Res. 2024 Oct 15;84(20):3419-3434. doi: 10.1158/0008-5472.CAN-24-0293. Cancer Res. 2024. PMID: 39402989 Free PMC article.
Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity.
Singh S, Gleason CE, Fang M, Laimon YN, Khivansara V, Xie S, Durmaz YT, Sarkar A, Ngo K, Savla V, Li Y, Abu-Remaileh M, Li X, Tuladhar B, Odeh R, Hamkins-Indik F, He D, Membreno MW, Nosrati M, Gushwa NN, Leung SSF, Fraga-Walton B, Hernandez L, Baldomero MP, Lent BM, Spellmeyer D, Luna JF, Hoang D, Gritsenko Y, Chand M, DeMart MK, Metobo S, Bhatt C, Shapiro JA, Yang K, Dupper NJ, Bockus AT, Doench JG, Aggen JB, Liu LF, Levin B, Wang EW, Vendrell I, Fischer R, Kessler B, Gokhale PC, Signoretti S, Spektor A, Kreatsoulas C, Singh R, Earp DJ, Garcia PD, Nijhawan D, Oser MG. Singh S, et al. Among authors: gokhale pc. bioRxiv [Preprint]. 2024 Aug 1:2024.08.01.605889. doi: 10.1101/2024.08.01.605889. bioRxiv. 2024. PMID: 39211113 Free PMC article. Preprint.
200 results